Tags

Type your tag names separated by a space and hit enter

Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.
Diagn Microbiol Infect Dis. 2011 Mar; 69(3):291-306.DM

Abstract

The CANWARD study (Canadian Ward Surveillance Study) assessed the antimicrobial susceptibility of a variety of available agents against 15 644 pathogens isolated from patients in Canadian hospitals between 2007 and 2009. The most active (based on MIC data) agents against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci were daptomycin, linezolid, tigecycline, and vancomycin (MRSA only) with MIC(90)'s (μg/mL) of 0.25 and 2, 2 and 2, 0.5 and 0.12, and 1, respectively. The most active agents against extended-spectrum β-lactamase-producing Escherichia coli were colistin (polymyxin E), doripenem, ertapenem, meropenem, and tigecycline with MIC(90)'s (μg/mL) of 1, ≤ 0.12, 0.25, ≤ 0.12, and 1, respectively. The most active agents against Pseudomonas aeruginosa were amikacin, cefepime, ceftazidime, colistin, doripenem, meropenem, and piperacillin-tazobactam with MIC(90)'s (μg/mL) of 32, 16, 32, 2, 4, 8, and 64, respectively. Overall, the most active agents versus Gram-positive cocci from Canadian hospitals were vancomycin, linezolid, daptomycin, and tigecycline and versus Gram-negative bacilli were amikacin, cefepime, doripenem, ertapenem (excluding Pseudomonas aeruginosa), meropenem, piperacillin-tazobactam, and tigecycline (excluding Pseudomonas aeruginosa).

Authors+Show Affiliations

Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0J9. ggzhanel@pcs.mb.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21353957

Citation

Zhanel, George G., et al. "Antimicrobial Susceptibility of 15,644 Pathogens From Canadian Hospitals: Results of the CANWARD 2007-2009 Study." Diagnostic Microbiology and Infectious Disease, vol. 69, no. 3, 2011, pp. 291-306.
Zhanel GG, Adam HJ, Low DE, et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011;69(3):291-306.
Zhanel, G. G., Adam, H. J., Low, D. E., Blondeau, J., Decorby, M., Karlowsky, J. A., Weshnoweski, B., Vashisht, R., Wierzbowski, A., & Hoban, D. J. (2011). Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagnostic Microbiology and Infectious Disease, 69(3), 291-306. https://doi.org/10.1016/j.diagmicrobio.2010.10.025
Zhanel GG, et al. Antimicrobial Susceptibility of 15,644 Pathogens From Canadian Hospitals: Results of the CANWARD 2007-2009 Study. Diagn Microbiol Infect Dis. 2011;69(3):291-306. PubMed PMID: 21353957.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. AU - Zhanel,George G, AU - Adam,Heather J, AU - Low,Donald E, AU - Blondeau,Joseph, AU - Decorby,Melanie, AU - Karlowsky,James A, AU - Weshnoweski,Barbara, AU - Vashisht,Ravi, AU - Wierzbowski,Aleksandra, AU - Hoban,Daryl J, AU - ,, PY - 2010/10/29/received PY - 2010/12/23/accepted PY - 2011/3/1/entrez PY - 2011/3/1/pubmed PY - 2011/9/6/medline SP - 291 EP - 306 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 69 IS - 3 N2 - The CANWARD study (Canadian Ward Surveillance Study) assessed the antimicrobial susceptibility of a variety of available agents against 15 644 pathogens isolated from patients in Canadian hospitals between 2007 and 2009. The most active (based on MIC data) agents against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci were daptomycin, linezolid, tigecycline, and vancomycin (MRSA only) with MIC(90)'s (μg/mL) of 0.25 and 2, 2 and 2, 0.5 and 0.12, and 1, respectively. The most active agents against extended-spectrum β-lactamase-producing Escherichia coli were colistin (polymyxin E), doripenem, ertapenem, meropenem, and tigecycline with MIC(90)'s (μg/mL) of 1, ≤ 0.12, 0.25, ≤ 0.12, and 1, respectively. The most active agents against Pseudomonas aeruginosa were amikacin, cefepime, ceftazidime, colistin, doripenem, meropenem, and piperacillin-tazobactam with MIC(90)'s (μg/mL) of 32, 16, 32, 2, 4, 8, and 64, respectively. Overall, the most active agents versus Gram-positive cocci from Canadian hospitals were vancomycin, linezolid, daptomycin, and tigecycline and versus Gram-negative bacilli were amikacin, cefepime, doripenem, ertapenem (excluding Pseudomonas aeruginosa), meropenem, piperacillin-tazobactam, and tigecycline (excluding Pseudomonas aeruginosa). SN - 1879-0070 UR - https://www.unboundmedicine.com/medline/citation/21353957/Antimicrobial_susceptibility_of_15644_pathogens_from_Canadian_hospitals:_results_of_the_CANWARD_2007_2009_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(10)00495-5 DB - PRIME DP - Unbound Medicine ER -